When Vitamin D Testing Is and Is Not Warranted

Vitamin D testing is neither useful for everyone nor wasteful for everyone. Its value depends on whether a person’s symptoms, medical conditions or risk factors make the result likely to change care. The 2024 Endocrine Society guideline reversal makes that distinction clearer, but it does not mean deficiency is unimportant or that every person at risk needs a blood test before taking a supplement.

What the 2024 Endocrine Society guideline actually reversed — and why it matters now

The Endocrine Society’s 2011 guideline set vitamin D sufficiency at ≥30 ng/mL. Its 2024 guideline reversed the society’s own position by dropping that target for healthy adults and recommending against routine testing in asymptomatic people without specific risk factors.

The test measures 25-hydroxyvitamin D [25(OH)D], which the liver makes from vitamin D that comes from food, supplements and skin synthesis. It is the accepted clinical proxy for whole-body vitamin D status. Yet being able to measure that status does not show that checking it routinely makes people healthier. Guidelines around the world largely agree that adults in the general population should not have routine screening. Vitamin D nevertheless remains one of the most-ordered labs in American primary care, leaving a gap between the guidance and everyday practice.

Why the RCT record drove the reversal — and what it found

Epidemiologic studies associated lower vitamin D levels with higher risks of respiratory infections, cardiovascular disease, malignancy and metabolic disorders. Those links helped testing expand after 2011. But an association does not establish that raising a blood level will prevent the associated disease. Randomized controlled trials, or RCTs, were needed to test whether supplementation delivered those benefits.

VITAL found that 2,000 IU/day vitamin D3 did not reduce total invasive cancer or major cardiovascular events in US adults. D-Health in Australia and FIND in Finland added to the null record for cardiovascular disease and cancer. DO-HEALTH, conducted across five European countries in adults 70 and older, found no benefit on fractures, infections, blood pressure, physical performance or cognition. That finding held even though roughly two-fifths of the people in the trial had deficiency when it began. Taken together, the trials offered a consistent result across populations, doses and continents rather than a finding peculiar to American adults.

These trials of supplementation weakened the premise that finding low levels and raising them would broadly prevent disease in the general population. The USPSTF independently judged the evidence on screening asymptomatic adults insufficient to weigh benefits against harms. It first took that position in 2014 and reaffirmed it in 2021. Insufficient evidence of benefit does not support routine screening.

Where deficiency is real and widespread, even if routine testing is not warranted

Even where deficiency is common, testing everyone may not be worthwhile. Its distribution is uneven, with higher rates in women than men and marked regional variation, including particularly high rates in the Eastern Mediterranean. Much of that variation reflects skin synthesis. Vitamin D is produced nonenzymatically in the epidermis through UV exposure, so latitude, season, skin pigmentation, indoor work and sun-protective behavior influence who runs low. Few foods naturally contain vitamin D, and most of what people get from their diet comes from fortified products.

This pattern matters because population prevalence cannot tell a clinician what a test will accomplish for one person. Prolonged deficiency has real consequences, including rickets in children and osteomalacia and fracture risk in adults. Reduced muscle strength and fall risk also make deficiency clinically important. But the failure of broad supplementation trials to prevent many outcomes cautions against treating every association as a benefit waiting to be unlocked. The useful next step is to distinguish people with a clinical reason for testing from people whose result would merely add another number to their records.

The clinical conditions and risk factors that make testing genuinely warranted

Anthem’s 2026 clinical UM guideline, CG-LAB-11, provides a detailed set of recognized indications. Chronic kidney disease can impair conversion of 25(OH)D to active calcitriol, while hepatic failure can impair 25-hydroxylation. Malabsorption conditions, including cystic fibrosis, inflammatory bowel disease, Crohn’s disease, celiac disease, bariatric surgery, chronic pancreatitis and radiation enteritis, can interfere with absorption. In these settings, the result can inform management of an existing problem.

Other indications concern how the body regulates vitamin D and calcium. They include parathyroid disorders, hypo- or hypercalcemia, and inherited disorders of vitamin D and phosphate metabolism. Granuloma-forming disorders, including sarcoidosis, tuberculosis, histoplasmosis, coccidioidomycosis and berylliosis, raise concern about vitamin D intoxication as well as deficiency. Lymphomas with activated macrophages also appear among the indications. This is an important limit on the assumption that a person at risk should simply take more vitamin D.

The guideline includes osteoporosis, osteomalacia, osteopenia and nutritional rickets, as well as immobilization associated with cerebral palsy or neuromuscular disease. Chronic use of enzyme-inducing medications is also relevant, including anti-seizure drugs, glucocorticoids, anti-retrovirals and antifungals. Previously documented deficiency and signs or symptoms of deficiency or intoxication provide further reasons to test.

The guideline also lists risks that have to do with a person’s stage of life, diet and limited skin synthesis. These include community-dwelling adults age 65 and older, severe obesity above the 95th percentile BMI, amenorrhea in adolescents, and prolonged breastfeeding in infants aged 6 months or older without appropriate complementary feeding. Other factors include vegan or macrobiotic diets, institutionalized living, limited mobility, aggressive sun protection and darker skin pigmentation. Higher latitudes during winter or spring, significant pollution or cloud cover, and pregnancy with added risks such as vegetarian diets or limited sun exposure also belong in the assessment. These factors call for a discussion of each person’s risks, rather than a rule for everyone based only on how common deficiency is.

The Cystic Fibrosis Foundation gives a concrete example of condition-specific monitoring. It recommends yearly vitamin D status screening for people with cystic fibrosis, preferably at the end of winter. For a previously low result followed by supplementation, retesting at 8–12 weeks allows roughly three half-lives for blood levels to stabilize. That is a different use of testing from repeatedly screening a healthy person without a clinical indication.

Four groups where the guideline recommends supplementation without testing first

The 2024 Endocrine Society guideline identifies four groups for empirical supplementation above the recommended dietary allowance without requiring testing first. For children and adolescents ages 1–18, the goals are to prevent rickets and potentially reduce respiratory infections. For pregnant patients, potential benefits include reductions in pre-eclampsia, intra-uterine mortality, preterm birth, small-for-gestational-age birth and neonatal mortality. Adults 75 and older may have a lower risk of death, while adults with high-risk prediabetes may progress more slowly toward type 2 diabetes.

The strength and interpretation of that evidence are not identical across the groups. The prediabetes recommendation rests on a pooled analysis of three trials, each of which was null on its primary endpoint. One also used an active vitamin D analogue rather than cholecalciferol, or vitamin D3. The American Diabetes Association reviewed the same data and has not issued a positive recommendation.

Current guidance calls for adults in general to get 600 IU daily through age 70 and 800 IU daily after age 70. Fortified foods or a supplement of up to 1,000 IU can provide that intake. These ordinary intake targets are distinct from the guideline’s higher-than-RDA recommendations for the four groups.

Where experts disagree — the threshold dispute that no trial has resolved

Even when testing is warranted, interpreting the result can be contentious. The Institute of Medicine set adequacy at ≥20 ng/mL in 2011, while the Endocrine Society’s 2011 guideline set sufficiency at ≥30 ng/mL using calcium absorption and parathyroid hormone, or PTH, suppression data. That difference can effectively double the proportion of people labeled deficient. The disagreement is therefore not just about terminology. It changes who receives a diagnosis and potentially treatment.

The 2024 Endocrine Society guideline concluded that evidence was insufficient to specify blood-level thresholds for adequacy or targets for disease prevention. Dropping its former target moved it away from the higher universal cutoff, but it did not establish a new universal answer. How much weight to give PTH, calcium absorption and observational associations compared with the null RCT record remains unresolved. Neither side has a trial that randomized patients to different serum targets. As a result, the same underlying evidence can support different judgments about what a low result means.

Precision-medicine advocates also argue that rejecting one-size-fits-all screening does not remove the need for population-specific decisions. Critics question applying adult trial findings to children with distinct vitamin D physiology. They also challenge recommendations against testing darker-skinned populations, pointing to the extremely high prevalence of insufficient levels among UK-dwelling South Asian and African-Caribbean individuals. This is a substantive disagreement about whose risks the evidence captures, including an equity concern. It leaves room for clinicians to use their judgment, but does not make the case for testing everyone.

The real cost of over-testing — beyond the lab bill

An unnecessary test can create financial, clinical and informational harm. CMS places strict frequency limits on vitamin D assays to prevent overuse after therapeutic levels have been reached. When there is no documented clinical indication for a test, insurance is increasingly likely to refuse to pay, leaving the patient to pay the full bill. An order from a clinician therefore does not by itself mean that insurance will pay. The reason for the test matters financially as well as medically.

The clinical risk begins when a result prompts treatment that was not needed. Randomized trials have linked high-dose supplementation in older adults to increased fall risk, the opposite of the intended effect. That undermines the idea that more is necessarily better. A number without an action plan can also trigger anxiety, unnecessary follow-up and supplementation decisions made without context. Over-testing is not harmless simply because the blood draw itself is routine.

A practical decision framework for individuals deciding whether to test

Consider testing when there is a specific clinical question. A condition affecting absorption or metabolism, relevant medication use, bone disease, symptoms of deficiency or intoxication, or a previous documented deficiency gives the result a purpose. Risks such as limited UV exposure, covered skin, institutionalized living or restrictions on what a person eats can also be reasons for assessment. Older age and severe obesity should be part of that discussion. The question to put to a clinician is what would change if the result were low, normal or high.

Consider supplementation without a baseline test when the guideline already supports it. The Endocrine Society’s four groups for empirical supplementation are children and adolescents, pregnant patients, adults 75 and older, and adults with high-risk prediabetes. The prediabetes recommendation carries the evidence dispute described above. Even with these recommendations, suspected intoxication or impaired metabolism can still be reasons to test.

Skip routine testing and supplementation beyond standard intake when there is no reason for either. For adults who are generally healthy and have no relevant conditions or risk factors, the large body of RCT evidence does not support those extra steps. That still leaves the standard RDA of 600–800 IU/day. When testing is warranted, late winter, including February–March in the Northern Hemisphere, offers the most conservative seasonal reading. Retesting after treatment of a documented low level serves a monitoring purpose.

Cost and interpretation complete the decision. A direct-to-consumer 25(OH)D assay with transparent pricing at $25–$50 is consistent with Medicare payment and can provide a clinically equivalent result to a hospital-ordered test. Sharing that result with a clinician closes the loop. Below 20 ng/mL conventionally indicates deficiency and 20–29 ng/mL insufficiency, but neither replaces the laboratory’s reference range and an assessment of individual context. Understanding why a result would change care is what puts a person in a stronger position to advocate for a warranted test, or decline an unnecessary one.